Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References FY 2022 guidance on other financial KPIs Barring unforeseen events; growth vs. PY in cc Group | full year guidance vs. PY (cc) Core Net Financial Result Core Tax Rate 25 Investor Relations | Q3 2022 Results Expenses expected to decrease by around 100-150m vs. 2021 (revised from broadly in line vs. 2021) Core tax rate expected to be around 16.5% (revised from 17-17.5%) NOVARTIS | Reimagining Medicine

View entire presentation